Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved..
Tumor-infiltrating lymphocytes (TILs), especially CD8+ TILs, represent a favorable prognostic factor in high-grade serous ovarian cancer (HGSOC) and other tumor lineages. Here, we analyze the spatial heterogeneity of different TIL subtypes in HGSOC. We integrated RNA sequencing, whole-genome sequencing, bulk T cell receptor (TCR) sequencing, as well as single-cell RNA/TCR sequencing to investigate the characteristics and differential composition of TILs across different HGSOC sites. Two immune "cold" patterns in ovarian cancer are identified: (1) ovarian lesions with low infiltration of mainly dysfunctional T cells and immunosuppressive Treg cells and (2) omental lesions infiltrated with non-tumor-specific bystander cells. Exhausted CD8 T cells that are preferentially enriched in ovarian tumors exhibit evidence for expansion and cytotoxic activity. Inherent tumor immune microenvironment characteristics appear to be the main contributor to the spatial differences in TIL status. The landscape of spatial heterogeneity of TILs may inform potential strategies for therapeutic manipulation in HGSOC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 3(2022), 12 vom: 20. Dez., Seite 100856 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Bin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
High-grade serous ovarian cancer |
|---|
| Anmerkungen: |
Date Completed 23.12.2022 Date Revised 08.01.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2022.100856 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350546975 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350546975 | ||
| 003 | DE-627 | ||
| 005 | 20231226045238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2022.100856 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350546975 | ||
| 035 | |a (NLM)36543113 | ||
| 035 | |a (PII)S2666-3791(22)00420-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Bin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2022 | ||
| 500 | |a Date Revised 08.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Tumor-infiltrating lymphocytes (TILs), especially CD8+ TILs, represent a favorable prognostic factor in high-grade serous ovarian cancer (HGSOC) and other tumor lineages. Here, we analyze the spatial heterogeneity of different TIL subtypes in HGSOC. We integrated RNA sequencing, whole-genome sequencing, bulk T cell receptor (TCR) sequencing, as well as single-cell RNA/TCR sequencing to investigate the characteristics and differential composition of TILs across different HGSOC sites. Two immune "cold" patterns in ovarian cancer are identified: (1) ovarian lesions with low infiltration of mainly dysfunctional T cells and immunosuppressive Treg cells and (2) omental lesions infiltrated with non-tumor-specific bystander cells. Exhausted CD8 T cells that are preferentially enriched in ovarian tumors exhibit evidence for expansion and cytotoxic activity. Inherent tumor immune microenvironment characteristics appear to be the main contributor to the spatial differences in TIL status. The landscape of spatial heterogeneity of TILs may inform potential strategies for therapeutic manipulation in HGSOC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a TILs | |
| 650 | 4 | |a high-grade serous ovarian cancer | |
| 650 | 4 | |a multi-omics | |
| 650 | 4 | |a multiple lesions | |
| 650 | 4 | |a spatial heterogeneity | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 700 | 1 | |a Li, Xiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Junpeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wenting |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiaohang |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Ensong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Si |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Dianxing |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Dou, Yingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Rourou |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Funian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zizhuo |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Tianyu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qinghua |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Shuaicheng |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Ding |e verfasserin |4 aut | |
| 700 | 1 | |a Mills, Gordon B |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Chaoyang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 3(2022), 12 vom: 20. Dez., Seite 100856 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2022 |g number:12 |g day:20 |g month:12 |g pages:100856 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2022.100856 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2022 |e 12 |b 20 |c 12 |h 100856 | ||